Active Surveillance for Prostate Cancer: When Is It an Option and What Happens Next?

TL;DR

• Active surveillance is an established approach for many men with low-risk localized prostate cancer and selected men with favorable intermediate-risk disease.
• It means delaying immediate treatment while the cancer is followed with scheduled tests such as PSA testing, clinical review, MRI, and repeat biopsy.
• The aim is to avoid or delay side effects from surgery or radiotherapy without losing the opportunity for treatment if the cancer shows important changes.
• Experiences shared through the mama health app highlight how important a clear follow-up plan, understandable explanations, and knowing what could prompt a change in approach can be.
• Active surveillance is different from watchful waiting. The choice depends on cancer characteristics, overall health, life expectancy, and personal preferences.

What is active surveillance for prostate cancer?

Active surveillance is a structured approach in which localized prostate cancer is followed closely rather than treated immediately.

The aim is to avoid or delay treatments such as surgery or radiotherapy when the cancer appears unlikely to cause harm in the near term. If follow-up tests indicate important changes, the healthcare team can discuss whether treatment has become appropriate.

Active surveillance is therefore not the same as ignoring prostate cancer. It involves planned medical follow-up.

Depending on the individual protocol, this may include:

• PSA blood tests
• Clinical appointments and sometimes digital rectal examination (DRE)
• Multiparametric MRI (mpMRI)
• Repeat prostate biopsies

The exact schedule varies between healthcare systems, clinics, and individual circumstances. MRI can provide additional information during surveillance, but major guidelines caution that it does not necessarily replace periodic biopsy.

For more background on how prostate cancer is classified, see mama health's guide to prostate cancer stages and its explanation of the Gleason score and Grade Groups.

When can active surveillance be an option?

Active surveillance is most commonly considered for low-risk localized prostate cancer and may also be considered for selected favorable intermediate-risk cancers.

Risk assessment involves more than simply knowing that a tumor is confined to the prostate. Doctors generally consider several pieces of information together, including:

• Grade Group and Gleason score
• PSA level and PSA density
• Clinical stage
• How much cancer was found on biopsy
• MRI findings
• Age and general health
• Estimated life expectancy
• Personal priorities and preferences

Grade Group 1, corresponding to Gleason 3+3=6, is commonly associated with active surveillance. Some carefully selected Grade Group 2 cancers, corresponding to Gleason 3+4=7, may also be considered depending on the amount of higher-grade disease and other risk factors.

European guidance describes active surveillance as an option for low-risk and some favorable intermediate-risk localized prostate cancers. It is not generally the standard approach for metastatic disease.

If terms such as Grade Group, Gleason score, or localized disease are unfamiliar, our guides to what the Gleason score means and prostate cancer stages I–IV explain them in more detail.

Is active surveillance the same as watchful waiting?

No. Active surveillance and watchful waiting both avoid immediate treatment, but their goals and follow-up strategies differ.

Active surveillance involves scheduled testing with the possibility of later treatment intended to control or cure localized disease if clinically important changes appear.

Watchful waiting generally involves less intensive testing. Its focus is usually on managing symptoms if they develop rather than repeatedly testing with the intention of identifying a point for curative treatment.

The distinction matters because the phrase "wait and see" can make active surveillance sound much more passive than it actually is.

Why might someone choose active surveillance?

The main reason to consider active surveillance is to avoid or postpone treatment-related side effects when immediate treatment may offer limited additional benefit.

Surgery and radiotherapy can be effective treatments for localized prostate cancer, but they can also affect urinary, sexual, and bowel function. For a cancer expected to behave slowly, immediate treatment can therefore expose someone to side effects before treatment is necessary.

Active surveillance creates another possibility: continue medical follow-up and reconsider treatment if the balance between its potential benefits and harms changes.

This can be particularly relevant because some prostate cancers grow slowly. You can read more about differences in disease behavior in our guide to how quickly prostate cancer can spread.

However, active surveillance has its own burdens. Repeat tests and biopsies can be uncomfortable, and living with a known cancer without treating it immediately can create uncertainty.

What is it like to live with prostate cancer on active surveillance?

Experiences shared through the mama health app suggest that the practical and emotional side of surveillance can matter just as much as understanding the medical definition.

Several recurring themes appear in stories shared by men living with prostate cancer. These experiences are individual and should not be interpreted as evidence that everyone will feel the same way.

A clear follow-up plan can make uncertainty easier to navigate

Knowing when the next PSA test, appointment, MRI, or biopsy is expected can provide structure. Uncertainty may feel more difficult when someone does not understand what happens next or why a particular test is being repeated.

Keeping appointment dates, questions, test results, and personal notes together can also make it easier to prepare for discussions with a healthcare professional.

Knowing what doctors are looking for can help

A common concern is not simply when is my next test? but what would make the plan change?

That distinction is important. A single PSA result does not necessarily mean that treatment is needed. The AUA/ASTRO guideline notes that transient PSA elevations can occur and that a rise may first be checked again. Persistent PSA changes, new examination findings, MRI findings, or changes seen on biopsy can lead to further assessment.

Understanding these possibilities can make conversations with the care team more concrete.

The emotional response is different for everyone

Some men describe reassurance from avoiding immediate treatment and its potential side effects. Others find the knowledge that cancer remains in the prostate difficult, particularly around PSA tests or follow-up appointments.

Neither reaction determines whether active surveillance is medically appropriate. Emotional wellbeing, personal preferences, and tolerance for uncertainty are reasonable subjects to discuss when considering the available options.

The experiences shared in mama health can help someone see the kinds of questions, concerns, and practical issues others have encountered. They do not predict an individual's course or replace advice from a healthcare professional.

What tests happen during active surveillance?

Active surveillance usually combines repeated PSA testing with clinical assessment, imaging, and periodic biopsy.

There is no single schedule that applies everywhere. Protocols are adjusted according to risk, previous results, age, general health, and local guidelines.

PSA testing

PSA is measured repeatedly to see how levels change over time. PSA can fluctuate for reasons other than cancer progression, so an isolated increase usually needs clinical interpretation rather than being considered on its own.

MRI

Multiparametric MRI can help doctors assess areas within the prostate and decide whether additional evaluation is appropriate. MRI has become an important part of modern risk assessment, but it should be considered alongside other information.

Repeat biopsy

A repeat biopsy allows prostate tissue to be examined again. It can identify changes in the amount or grade of cancer that may not be apparent from PSA alone.

Clinical review

Appointments provide an opportunity to review test results, general health, symptoms, preferences, and whether the current strategy still makes sense.

These tests work together. No single PSA result, MRI finding, or symptom should be interpreted outside its clinical context.

What could lead to treatment after active surveillance?

Treatment may be discussed if follow-up identifies evidence that the cancer has become more clinically significant or if personal circumstances and preferences change.

Possible reasons for reconsidering surveillance can include:

• A higher Grade Group on a subsequent biopsy
• An increase in the volume of higher-grade cancer
• Concerning changes on MRI
• Repeated PSA changes that lead to further investigation
• Other clinical evidence suggesting progression
• A change in personal preferences after discussing benefits and risks

A rising PSA alone does not automatically mean that surveillance has failed.

Guidelines emphasize reassessing the overall picture. Biopsy findings, imaging, PSA, age, health, life expectancy, and personal preferences can all contribute to the discussion.

Does choosing active surveillance mean treatment options disappear later?

Active surveillance is designed to preserve the possibility of definitive treatment if clinically important progression is identified.

When treatment becomes appropriate, options may include radical prostatectomy or radiotherapy, depending on the cancer's characteristics and the individual's health and preferences.

The specific options available later cannot be guaranteed in advance. They depend on what subsequent examinations show.

This is why surveillance needs to be structured. Its purpose is not simply to postpone treatment indefinitely, but to follow the cancer closely enough for the healthcare team to reassess the plan when necessary.

For a broader overview, see mama health's guide to prostate cancer, symptoms, therapies, and life expectancy.

What are useful questions to discuss with a doctor?

Questions about eligibility, follow-up, and the circumstances that could change the plan can make an active-surveillance discussion more useful.

Questions that others have found helpful to prepare include:

1. Could active surveillance be considered with my Grade Group, PSA, biopsy, and MRI findings?
2. What would my follow-up schedule involve?
3. How frequently would PSA testing, MRI, and biopsy be considered?
4. What changes would lead you to investigate further?
5. What findings could lead us to discuss treatment?
6. How would my age and general health affect the decision?
7. What are the potential benefits and disadvantages of starting treatment now compared with surveillance?
8. If treatment is needed later, what options might be considered?

These are prompts for a conversation rather than recommendations about what someone should choose.

How can mama health support someone living with prostate cancer?

mama health provides a place to explore trusted information, reflect on personal experiences, and prepare questions for healthcare appointments.

The app also makes it possible to explore experiences shared by others living with prostate cancer. Those stories can provide useful context around topics that clinical definitions may not fully capture: waiting for a PSA result, preparing for another biopsy, managing uncertainty, talking with family, or deciding what to ask at the next appointment.

mama health can also help organize personal reflections and make medical terminology easier to understand. It does not diagnose prostate cancer, assess whether active surveillance is suitable for an individual, interpret results for clinical decision-making, or recommend treatment.

Explore mama health's prostate cancer condition page for more educational information and lived experiences.

What is the bottom line on active surveillance?

Active surveillance is an established option that can allow selected men with localized prostate cancer to delay or avoid immediate treatment while remaining under structured medical follow-up.

It is particularly relevant to low-risk disease and can also be considered in carefully selected favorable intermediate-risk cases.

The decision is individual. Grade Group, PSA, biopsy findings, imaging, age, overall health, life expectancy, and personal priorities all matter.

Experiences shared through mama health also underline another part of the decision: understanding the plan can matter. Knowing what the next test is for, what doctors are watching for, and what could lead to another discussion may make an uncertain period easier to navigate.

Active surveillance is not "doing nothing." It is a defined approach with regular reassessment and the possibility of treatment if circumstances change.

Disclaimer: This content is informational. mama health offers information and support and does not replace a doctor.